FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Opioid Use

  • Home
  •  | 
  • Tag Archives: "Opioid Use"

Columbia University Receives National Institute on Drug Abuse (NIDA) Research Grant to Study Impact of Medical Cannabis on Opioid Use in Collaboration with Columbia Care

Columbia University Receives National Institute on Drug Abuse (NIDA) Research Grant to Study Impact of Medical Cannabis on Opioid Use in Collaboration with Columbia Care
The Columbia University Department of Psychiatry and Columbia Care LLC, the nation’s leading medical cannabis company, today announced that researchers from Columbia University have been awarded an R21 research grant from the National Institute on Drug Abuse (NIDA) to study, in collaboration with Columbia Care, the potential mechanisms of how using Columbia Care’s formulated dose-metered cannabinoid medicines influences opioid use and overdose risk among patients with non-cancer pain conditions.
Read more

Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA

Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA
Sept. 27, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinol AdVersa™ mucoadhesive product, PPP002. The purpose of the meeting was to obtain confirmation of the eligibility of PPP002 for the 505(b)(2) NDA and the requirements for marketing approval.
Read more